“…Twenty-one monoterpenoids were reported in our Review, among which ten exhibited high in vitro antibacterial activity. All of them were found in EOs from plants and have received much attention for their significant antibacterial activity, with four compounds (α-terpineol, carvacrol, eucalyptol, and thymol) being investigated with in vivo models of bacterial infections, ,− and six (α-pinene, carvacrol, eucalyptol, linalool, terpinen-4-ol, and thymol) tested in clinical trials (Table ) related to infectious and inflammatory conditions (e.g., gingivitis, sore throat, episiotomy, acute bronchitis, blepharitis). ,, Although highly active, these compounds present some drawbacks reducing their use as antibacterial agents, especially their unfavorable physicochemical profile with high volatility leading to instability and a short half-life, a low water solubility leading to a poor bioavailability after oral administration, an unpleasant taste and smell, and potential toxicity due to poor knowledge concerning the optimal safe dose to be administered. Future research directions include improvement of physicochemical properties, the examination of acute and chronic toxicity as well as teratogenicity, development of standardized formulations with multiple compounds, and realization of clinical trials focused on multidrug resistant bacterial infections.…”